Less Success 'Expected' In 'OTC Setting' Trial For GSK's NRT, Expert Tells NDAC
Executive Summary
While lower than results in GSK standard efficacy trial, 'real world' success still is clinically significant, firm's experts tell FDA advisory committee after agency officials asked the panel to consider whether the results translate to clinically meaningful benefit for GSK's proposed mouth spray NRT.